AUGMEDIX INC (AUGX) Stock Fundamental Analysis

USA • Nasdaq • NASDAQ:AUGX • US05105P1075

2.35 USD
0 (0%)
At close: Oct 1, 2024
2.35 USD
0 (0%)
After Hours: 10/1/2024, 8:00:01 PM
Fundamental Rating

2

Taking everything into account, AUGX scores 2 out of 10 in our fundamental rating. AUGX was compared to 35 industry peers in the Health Care Technology industry. Both the profitability and financial health of AUGX have multiple concerns. AUGX is valied quite expensively at the moment, while it does show a decent growth rate.


Dividend Valuation Growth Profitability Health

1

1. Profitability

1.1 Basic Checks

  • In the past year AUGX has reported negative net income.
  • AUGX had a negative operating cash flow in the past year.
  • In the past 5 years AUGX always reported negative net income.
  • AUGX had a negative operating cash flow in each of the past 5 years.
AUGX Yearly Net Income VS EBIT VS OCF VS FCFAUGX Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2018 2019 2020 2021 2022 2023 -5M -10M -15M -20M

1.2 Ratios

  • The Return On Assets of AUGX (-44.44%) is worse than 65.79% of its industry peers.
  • Looking at the Return On Equity, with a value of -227.72%, AUGX is doing worse than 81.58% of the companies in the same industry.
Industry RankSector Rank
ROA -44.44%
ROE -227.72%
ROIC N/A
ROA(3y)-44.98%
ROA(5y)-61.67%
ROE(3y)-606%
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
AUGX Yearly ROA, ROE, ROICAUGX Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2018 2019 2020 2021 2022 2023 0 -500 -1K -1.5K

1.3 Margins

  • AUGX has a Gross Margin of 48.21%. This is in the lower half of the industry: AUGX underperforms 60.53% of its industry peers.
  • In the last couple of years the Gross Margin of AUGX has grown nicely.
  • AUGX does not have Profit Margin and Operating Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 48.21%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y5.22%
GM growth 5Y45.73%
AUGX Yearly Profit, Operating, Gross MarginsAUGX Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2018 2019 2020 2021 2022 2023 0 -50 -100 -150 -200

More info and screens

2

2. Health

2.1 Basic Checks

  • AUGX does not have a ROIC to compare to the WACC, probably because it is not profitable.
  • Compared to 1 year ago, AUGX has more shares outstanding
  • Compared to 1 year ago, AUGX has an improved debt to assets ratio.
AUGX Yearly Shares OutstandingAUGX Yearly Shares OutstandingYearly Shares Outstanding 2018 2019 2020 2021 2022 2023 10M 20M 30M 40M
AUGX Yearly Total Debt VS Total AssetsAUGX Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2018 2019 2020 2021 2022 2023 20M 40M 60M

2.2 Solvency

  • Based on the Altman-Z score of -2.71, we must say that AUGX is in the distress zone and has some risk of bankruptcy.
  • With a Altman-Z score value of -2.71, AUGX is not doing good in the industry: 65.79% of the companies in the same industry are doing better.
  • AUGX has a Debt/Equity ratio of 1.48. This is a high value indicating a heavy dependency on external financing.
  • AUGX has a worse Debt to Equity ratio (1.48) than 84.21% of its industry peers.
Industry RankSector Rank
Debt/Equity 1.48
Debt/FCF N/A
Altman-Z -2.71
ROIC/WACCN/A
WACC9%
AUGX Yearly LT Debt VS Equity VS FCFAUGX Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2018 2019 2020 2021 2022 2023 0 10M -10M 20M -20M

2.3 Liquidity

  • AUGX has a Current Ratio of 1.66. This is a normal value and indicates that AUGX is financially healthy and should not expect problems in meeting its short term obligations.
  • The Current ratio of AUGX (1.66) is comparable to the rest of the industry.
  • AUGX has a Quick Ratio of 1.66. This is a normal value and indicates that AUGX is financially healthy and should not expect problems in meeting its short term obligations.
  • AUGX has a Quick ratio (1.66) which is comparable to the rest of the industry.
Industry RankSector Rank
Current Ratio 1.66
Quick Ratio 1.66
AUGX Yearly Current Assets VS Current LiabilitesAUGX Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2018 2019 2020 2021 2022 2023 10M 20M 30M 40M 50M

More info and screens

6

3. Growth

3.1 Past

  • AUGX shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 15.66%, which is quite good.
  • Looking at the last year, AUGX shows a very strong growth in Revenue. The Revenue has grown by 39.34%.
  • Measured over the past years, AUGX shows a very strong growth in Revenue. The Revenue has been growing by 32.90% on average per year.
EPS 1Y (TTM)15.66%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-8.33%
Revenue 1Y (TTM)39.34%
Revenue growth 3Y39.62%
Revenue growth 5Y32.9%
Sales Q2Q%26.75%

3.2 Future

  • AUGX is expected to show a small growth in Earnings Per Share. In the coming years, the EPS will grow by 6.46% yearly.
  • The Revenue is expected to grow by 11.58% on average over the next years. This is quite good.
EPS Next Y-20.13%
EPS Next 2Y-3.76%
EPS Next 3Y6.46%
EPS Next 5YN/A
Revenue Next Year18.97%
Revenue Next 2Y22.71%
Revenue Next 3Y11.58%
Revenue Next 5YN/A

3.3 Evolution

  • The estimated forward Revenue growth is still strong, although it is decreasing when compared to the stronger growth in the past years.
AUGX Yearly Revenue VS EstimatesAUGX Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2018 2019 2020 2021 2022 2023 2024 2025 2026 20M 40M 60M
AUGX Yearly EPS VS EstimatesAUGX Yearly EPS VS EstimatesYearly EPS VS Estimates 2021 2022 2023 2024 2025 2026 -0.2 -0.4 -0.6

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

  • AUGX reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
  • Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for AUGX. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
AUGX Price Earnings VS Forward Price EarningsAUGX Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
AUGX Per share dataAUGX EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 0.5 1

4.3 Compensation for Growth

PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y-3.76%
EPS Next 3Y6.46%

More info and screens

0

5. Dividend

5.1 Amount

  • No dividends for AUGX!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

AUGMEDIX INC

NASDAQ:AUGX (10/1/2024, 8:00:01 PM)

After market: 2.35 0 (0%)

2.35

0 (0%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupHealth Care Equipment & Services
GICS IndustryHealth Care Technology
Earnings (Last)08-12
Earnings (Next)11-04
Inst Owners72.68%
Inst Owner Change0%
Ins Owners11.72%
Ins Owner Change0%
Market Cap116.16M
Revenue(TTM)51.59M
Net Income(TTM)-23.85M
Analysts80
Price Target3.6 (53.19%)
Short Float %N/A
Short RatioN/A
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)8.31%
Min EPS beat(2)4.41%
Max EPS beat(2)12.2%
EPS beat(4)4
Avg EPS beat(4)11.24%
Min EPS beat(4)4.41%
Max EPS beat(4)16.56%
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)0
Avg Revenue beat(2)-1.48%
Min Revenue beat(2)-1.76%
Max Revenue beat(2)-1.2%
Revenue beat(4)1
Avg Revenue beat(4)-0.56%
Min Revenue beat(4)-1.76%
Max Revenue beat(4)0.98%
Revenue beat(8)4
Avg Revenue beat(8)0.08%
Revenue beat(12)5
Avg Revenue beat(12)-0.26%
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)1.29%
EPS NQ rev (1m)0%
EPS NQ rev (3m)5.74%
EPS NY rev (1m)0%
EPS NY rev (3m)1.85%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)-4.06%
Revenue NY rev (1m)0%
Revenue NY rev (3m)-2.64%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 2.25
P/FCF N/A
P/OCF N/A
P/B 11.09
P/tB 11.09
EV/EBITDA N/A
EPS(TTM)-0.44
EYN/A
EPS(NY)-0.48
Fwd EYN/A
FCF(TTM)-0.36
FCFYN/A
OCF(TTM)-0.31
OCFYN/A
SpS1.04
BVpS0.21
TBVpS0.21
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA -44.44%
ROE -227.72%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 48.21%
FCFM N/A
ROA(3y)-44.98%
ROA(5y)-61.67%
ROE(3y)-606%
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y5.22%
GM growth 5Y45.73%
F-Score5
Asset Turnover0.96
Health
Industry RankSector Rank
Debt/Equity 1.48
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 180.82%
Cap/Sales 4.95%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 1.66
Quick Ratio 1.66
Altman-Z -2.71
F-Score5
WACC9%
ROIC/WACCN/A
Cap/Depr(3y)178.38%
Cap/Depr(5y)139.24%
Cap/Sales(3y)4.74%
Cap/Sales(5y)4.8%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)15.66%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-8.33%
EPS Next Y-20.13%
EPS Next 2Y-3.76%
EPS Next 3Y6.46%
EPS Next 5YN/A
Revenue 1Y (TTM)39.34%
Revenue growth 3Y39.62%
Revenue growth 5Y32.9%
Sales Q2Q%26.75%
Revenue Next Year18.97%
Revenue Next 2Y22.71%
Revenue Next 3Y11.58%
Revenue Next 5YN/A
EBIT growth 1Y-14.13%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year-19.28%
EBIT Next 3Y9.53%
EBIT Next 5YN/A
FCF growth 1Y12.92%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y21.91%
OCF growth 3YN/A
OCF growth 5YN/A

AUGMEDIX INC / AUGX FAQ

Can you provide the ChartMill fundamental rating for AUGMEDIX INC?

ChartMill assigns a fundamental rating of 2 / 10 to AUGX.


What is the valuation status of AUGMEDIX INC (AUGX) stock?

ChartMill assigns a valuation rating of 0 / 10 to AUGMEDIX INC (AUGX). This can be considered as Overvalued.


Can you provide the profitability details for AUGMEDIX INC?

AUGMEDIX INC (AUGX) has a profitability rating of 1 / 10.


What is the expected EPS growth for AUGMEDIX INC (AUGX) stock?

The Earnings per Share (EPS) of AUGMEDIX INC (AUGX) is expected to decline by -20.13% in the next year.